title: [Immunological study in carcinogenesis. Distribution of tissue incompatibility antigens (system HL-A) in oncological patients].
abstract: By means of a micromethod of lymphocytotoxic test the content of eleven HL-A antigens (1, 2, 3, 5, 7, 8, 9, 10, 11, 12 and 13) was studied in 200 healthy human subjects, 100 patients with rheumatoid polyarthritis and 82 patients with bone tumors. The latter included 50 patients with benign tumors (osteoblastoclastomas, chondroblastomas, chondromas, non-osteogenic fibromas) and 32 patients with malignant tumors (chondro- and osteosarcomas, Ewing sarcoma, malignant osteoblastoclastomas). It was found that in patients with different bone tumors antigen HL-7 was encountered reliably more frequently than in control groups, in patients with malignant tumor also antigen HL-A10 was more often detected. The most frequently observed haplotyes in oncological patients were HL-A3/7 and HL-A2/7. In patients with rheumatoid polyarthritis antigen HL-A3 was found more rarely and antigen HL-A10 more frequently than in healthy subjects. The most frequent haplotypes in this group were as follows: HL-A2/7, HL-A2/8 and HL-A11/12. The possible mechanisms of the relationship between HL-A antigens and the development of pathology are discussed. Some considerations are offered concerning the possibility to utilize HL-A typing for an accessory differential diagnosis.
mesh_terms: D001172:Arthritis, Rheumatoid / Q000276:immunology; D001859:Bone Neoplasms / Q000276:immunology*; D002812:Chondroma / Q000276:immunology; D002813:Chondrosarcoma / Q000276:immunology; D003937:Diagnosis, Differential; D005350:Fibroma / Q000276:immunology; D005870:Giant Cell Tumors / Q000276:immunology; D006680:HLA Antigens / Q000032:analysis; D006649:Histocompatibility Antigens; D006801:Humans; D012516:Osteosarcoma / Q000276:immunology; D012512:Sarcoma, Ewing / Q000276:immunology
chemical_list: D006680:HLA Antigens; D006649:Histocompatibility Antigens
vernacular_title: Immunologicheskie issledovaniia pri kantserogeneze. Raspredelenie antigenov tkanevoĭ nesovmestimosti (sistemy HL-A) u onkologicheskikh bol'nykh